IDENTIFICATION OF TUMOR SPECIFIC T LYMPHOCYTES FROM PERIPHERAL BLOOD OF CANCER

尽管有可能分离出T淋巴细胞的克隆， 针对自体肿瘤细胞的特异性细胞毒性， 所涉及的技术是费力的。 更方便的检测方法， 细胞毒性T细胞（CTL）将简化免疫反应的研究， 肿瘤，并将促进全身免疫的研究 正在接受免疫治疗的癌症患者的反应， 肿瘤疫苗治疗 新型ELISPOT检测使用外周血 来自患者的T细胞，其通过体外暴露于 从手术获得的相同样品中获得的膜 病人的癌症。 在以前的研究中，我们已经证明了T- 小鼠和人的细胞与细胞膜是有效的和具体的。 我们还观察到，接受疫苗接种的患者的T细胞 一系列癌症的方案可以通过以下方式特异性刺激 这些细胞膜来自于这些病人的癌症。 本 在这项研究中，我们将把这项分析扩展到更多的癌症患者。 在不同的阶段， 用于评估对肿瘤的免疫应答的基线。

Although it is possible to isolate clones of T-lymphocytes which have specific cytotoxicity directed against autologous tumor cells, the techniques involved are laborious. More convenient assays for specific cytotoxic T-cells (CTLs) would simplify the study of immune response to tumors and would facilitate the investigation of systemic immune responses in cancer patients who are undergoing immunotherapy such as tumor vaccine therapy. The novel ELISPOT assay uses peripheral blood T-cells from patients which are stimulated by exposure in vitro to membranes derived from a surgically obtained sample of the same patient's cancer. In a previous we have shown that stimulation of T- cells of mice and men with cellular membranes is effective and specific. We have also observed that T-cells of patients undergoing a vaccination protocol with an array of cancers could be stimulated specifically by the membranes derived from those patients' cancers. In the present study we will expand this analysis to a larger number of cancer patients with a broader variety of cancers, and at different stages, to establish a baseline for evaluating immune response to tumors.